DexCom (NASDAQ:DXCM) Announces Earnings Results, Beats Expectations By $0.09 EPS

DexCom (NASDAQ:DXCM) issued its quarterly earnings data on Thursday. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09, Zacks reports. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.DexCom’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS.

Here are the key takeaways from DexCom’s conference call:

• Company reported Q1 revenue of $1.19 billion (up 15% YoY, organic +12%), with gross margin improving to 63.5%, operating income and adjusted EBITDA up materially, and management reaffirmed FY revenue guidance while raising operating profit and EBITDA margin guidance.
• Product momentum from the G7 15‑Day rollout was strong — customers praised the longer wear and improved algorithm (company estimates ~50% of base will convert by year‑end) — and Dexcom is deploying adhesive and software (Stelo redesign, Smart Basal pilot) updates to further drive adoption and retention.
• Payer access is expanding — Prime Therapeutics will cover Dexcom CGM for commercial type‑2 non‑insulin patients this summer, putting coverage at >7 million non‑insulin lives by year‑end, and a randomized control trial readout at ADA 2026 is expected to support broader reimbursement efforts.
• Management reiterated gross margin guidance but flagged a 50–100 bps potential headwind from geopolitical/fuel and resin price uncertainty, leaving timing for broader CMS coverage for type‑2 non‑insulin patients still uncertain.
• Cash generation was strong — ending the quarter with ~$2.4 billion in cash and significant free cash flow — giving flexibility for capital allocation (buybacks, tuck‑ins, manufacturing investments) that management plans to discuss at Investor Day.

DexCom Trading Up 3.5%

Shares of NASDAQ DXCM traded up $1.99 during trading on Thursday, reaching $59.55. The company had a trading volume of 5,332,816 shares, compared to its average volume of 4,013,830. The company’s fifty day moving average price is $65.87 and its 200-day moving average price is $66.40. DexCom has a 12 month low of $54.11 and a 12 month high of $89.98. The stock has a market cap of $22.98 billion, a P/E ratio of 28.36, a PEG ratio of 1.12 and a beta of 1.55. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the sale, the executive vice president owned 111,204 shares in the company, valued at approximately $7,010,300.16. The trade was a 1.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently made changes to their positions in DXCM. DV Equities LLC bought a new stake in shares of DexCom in the 4th quarter valued at about $36,000. Aster Capital Management DIFC Ltd bought a new stake in shares of DexCom in the 4th quarter valued at about $63,000. Quarry LP acquired a new position in shares of DexCom in the 3rd quarter valued at about $72,000. Summit Securities Group LLC lifted its stake in shares of DexCom by 817.2% in the 4th quarter. Summit Securities Group LLC now owns 1,174 shares of the medical device company’s stock valued at $78,000 after purchasing an additional 1,046 shares during the period. Finally, Palisade Asset Management LLC acquired a new position in shares of DexCom in the 3rd quarter valued at about $81,000. Institutional investors own 97.75% of the company’s stock.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q1 results beat expectations — EPS $0.56 vs. $0.47 consensus and revenue $1.19B vs. ~$1.17B consensus; revenue grew ~15% year‑over‑year, supporting the beat. Read More.
• Positive Sentiment: Underlying profitability and returns remain strong (reported net margin ~17.9% and ROE ~32%), reinforcing the business quality of its continuous glucose monitor (CGM) franchise. Read More.
• Neutral Sentiment: Management reaffirmed full‑year revenue guidance at roughly $5.2–5.3B (company cited a FY revenue target near $5.21B), a range that is roughly in line with consensus but left little upside. Read More.
• Neutral Sentiment: Company posted its press release, slide deck and conference‑call materials for investors to review — useful for digging into regional demand, reimbursement trends, and product cadence. Read More.
• Negative Sentiment: Market reaction was negative after hours: several outlets report shares dropped on concerns that the revenue guidance and lack of clearer upside for FY26 were disappointing relative to the beat. That suggests investors were looking for stronger forward acceleration or additional margin/cost leverage. Read More.
• Negative Sentiment: Coverage notes the stock “dipped after hours” despite beats — a reminder that beats alone may not drive gains unless guidance or cadence implies future upside above consensus. Read More.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Truist Financial restated a “buy” rating and set a $80.00 price objective (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Robert W. Baird set a $87.00 price objective on DexCom in a research report on Friday, February 13th. Wells Fargo & Company reduced their price objective on DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Weiss Ratings upgraded DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. Finally, BTIG Research restated a “buy” rating and set a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $86.50.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.